Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
A NETRF-funded researcher earned the highest honor from the American Society of Clinical Oncology (ASCO) on June 3, 2017 as part of its Annual Meeting in Chicago. Carl June, MD, University of Pennsylvania, received the David A. Karnofsky Memorial Award for outstanding contributions to cancer research, diagnosis, and treatment.
Study shows rising incidence and prevalence of NETs. Plus people living longer with neuroendocrine cancer. This means more people living with NETs.
Growing small intestinal organoids in a petri dish. Sequencing the “runaway” DNA of a pancreatic neuroendocrine tumor from a blood sample. Evaluating whether environmental or infectious agents contribute to the development of NETs. The research programs funded by NETRF this year push the search for the causes of this disease to the horizon of emerging scientific research.
(April 25, 2017, Boston, MA)—The Neuroendocrine Tumor Research Foundation (NETRF) today announced its largest research commitment ever—$4 million in collaborative grants—most from its new Accelerator
NETRF’s strong financial position, transparency, and accountability again earned it a 4-star rating by Charity Navigator, a national evaluator of nonprofits. The 4-star rating indicates
NETRF is pleased to announce awards for world-class research to explore the potential of immunotherapy in NETs. This rapidly expanding class of therapies has proven
Michael German, MD has been named a Petersen Investigator for his work to explore the use of an FDA approved inhibitor of Mek1/2 in preclinical
The Neuroendocrine Tumor Research Foundation is excited to be working with Pattern.org to empower patients to direct their excess cancer tissue samples to research projects.
The first NETRF/ERF Nuclear Medicine Pilot Research Grant has been awarded to Thomas Hope, MD, of the University of California at San Francisco (UCSF). NETRF
The NETRF Board of Directors is pleased to announce that Josh Mailman has joined the Board. Josh is an internationally-recognized advocate for Neuroendocrine tumor patients